Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 16/20 | 0.59 |
| ▸ | ITGAV | P06756 | 12/20 | 0.59 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.59 |
| ▸ | ITGA5 | P08648 | 2/20 | 0.59 |
| ▸ | ITGB5 | P18084 | 6/20 | 0.51 |
| ▸ | MC4R | P32245 | 3/20 | 0.50 |
| ▸ | MC5R | P33032 | 3/20 | 0.50 |
| ▸ | MC3R | P41968 | 3/20 | 0.50 |
| ▸ | MC1R | Q01726 | 3/20 | 0.50 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.46 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.46 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8205616 | 1.00 | ITGB3 (0.59) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL14075704 | 0.92 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL278822 | 0.91 | ITGB3 (0.47) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL13918138 | 0.86 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL14075695 | 0.86 | ITGB3 (0.53) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL13446003 | 0.85 | ITGB3 (0.51) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL13445979 | 0.84 | ITGB3 (0.50) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL13481604 | 0.84 | ITGB3 (0.52) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL7744481 | 0.83 | ITGB3 (0.64) | ITGB3ITGAVITGB1ITGA5ITGB5 | |
| SCHEMBL279121 | 0.83 | ITGB3 (0.64) | ITGB3ITGAVITGB1ITGA5ITGB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7666392-B2 | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-7666392-B2 | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-02-23 | — | — | US | disclosed |
| US-20080170992-A1 | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2008-07-17 | — | — | US | disclosed |
| US-20080170992-A1 | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2008-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080170992-A1 | Click chemistry-derived cyclopeptide derivatives as imaging agents for integrins | ITGB3, VCAM1, ITGB1 | ITGB3 1/4885ITGAV 5/4885ITGB1 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.